Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla also allayed concerns that the US government's drug pricing executive order on pharma companies, aimed at lowering cost ...

Cipla, India's No. 3 drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by strong ...

FY25 net profit beat expectations due to higher other income and a lower tax outgo, EBITDA came in slightly below estimates because of increased R&D expenditure.

For the new financial year, Cipla expects its topline to see "continued growth trajectory" and the management fell short of ...

Discover the Cipla Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Cipla's stock experienced a decline in today's session, with the price decreasing by 1.45% to Rs 1498.10. There was high ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

The pharmaceutical segment contributed Rs 6,503.63 crore to the quarterly revenue, reflecting an 8.5 per cent growth, while ...

May 13 (Reuters) - Cipla (CIPL.NS), opens new tab, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by strong demand for its drugs ...

Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, with broad-based ...

Shares of HAL, Tata Power, Eicher Motors and Jubilant Food are expected to be in the spotlight today as these companies are ...